ACM
BCRX icon

AlphaCrest Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

AlphaCrest Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-49,026
Closed -$618K – 132
2022
Q3 		$618K Buy
49,026
+32,405
+195% +$417K 0.04% 883
2022
Q2 		$176K Buy
+16,621
New +$171K 0.01% 1214

Other funds holding BCRX

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

AlphaCrest Capital Management's BCRX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 49,026 shares — an estimated $618K sold.

AlphaCrest Capital Management first reported a position in BCRX in Q2 2022 and held it in 2 quarters. The position peaked at $618K in Q3 2022. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 49,026 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $618K.
  • AlphaCrest Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • AlphaCrest Capital Management's BioCryst Pharmaceuticals position peaked at $618K in Q3 2022.
  • 230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.